Embecta Tidigare resultatutveckling
Tidigare kriterier kontrolleras 4/6
Embecta s intäkter har minskat med en genomsnittlig årlig takt på -43.6%, medan Medical Equipment -branschen såg intäkter på växande 12.1% årligen. Intäkterna har varit fallande med en genomsnittlig takt på 1.9% per år.
Viktig information
-43.62%
Tillväxttakt i vinsten
-43.12%
Tillväxttakt för EPS
| Medical Equipment Tillväxt i branschen | 8.90% |
| Intäkternas tillväxttakt | -1.92% |
| Avkastning på eget kapital | n/a |
| Nettomarginal | 10.73% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Analysuppdatering • Apr 30
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.Analysuppdatering • Apr 15
EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Seeking Alpha • Mar 19
Embecta: An Interesting Deal At An Interesting Time
Summary Embecta trades at multi-year lows due to GLP-1 overhang and flat sales but maintains strong margins and a >6% dividend yield. Embecta's £150M acquisition of Owen Mumford adds higher-growth exposure, is strategically sound, and is priced at a reasonable 1.4–2x sales multiple. Leverage will rise to 3.3x EBITDA post-deal but appears manageable given stable cash flows and robust profitability. I am cautiously upbeat, seeing deep value at 3x earnings, but prefer a small position due to near-term dilution and leverage concerns. Read the full article on Seeking Alpha
Analysuppdatering • Feb 18
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).Analysartikel • Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...Analysartikel • Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 2.4% to close at US$10.87 following the...Analysartikel • Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...Analysuppdatering • Feb 03
EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.Analysuppdatering • Jan 20
EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.Analysartikel • Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...Analysuppdatering • Jan 05
EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).Analysuppdatering • Dec 15
EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.Analysartikel • Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
It's been a sad week for Embecta Corp. ( NASDAQ:EMBC ), who've watched their investment drop 14% to US$12.57 in the...Analysartikel • Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it saw a significant share price rise of 36...Analysartikel • Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for Embecta is US$27.21 based on 2 Stage Free Cash Flow to Equity Embecta's...Analysartikel • Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Despite an already strong run, Embecta Corp. ( NASDAQ:EMBC ) shares have been powering on, with a gain of 29% in the...Analysuppdatering • Aug 10
GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.Analysartikel • Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 11.4x might make it look like a buy right now...Analysartikel • May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Analysartikel • May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...Analysartikel • Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Key Insights Embecta's estimated fair value is US$24.29 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • Feb 28
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Summary Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. However, the expanding diabetes care market should partially offset these headwinds, leading to flat topline growth in the coming years. Even though the company is going to post a flat topline, its valuation is such that the business is going to go bust in some time. This situation offers a good risk reward to go long on the stock. Read the full article on Seeking AlphaSeeking Alpha • Dec 04
New Initiatives Expected To Make Embecta More Profitable
Summary Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. I have upgraded the rating on EMBC stock to a Buy, expecting a 12.0% share price increase over the next year, driven by restructuring and new revenue streams. Read the full article on Seeking AlphaAnalysartikel • Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Embecta Corp. ( NASDAQ:EMBC ) will pay a dividend of $0.15 on the 18th of December. The dividend yield will be 2.9...Analysartikel • Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Analysartikel • Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 12.6x might make it look like a buy right now...
Ny analys • Sep 16
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Analysartikel • Aug 16
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Analysartikel • Aug 14
Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 3.1% to close at US$14.82 following the...Analysartikel • Jul 13
When Should You Buy Embecta Corp. (NASDAQ:EMBC)?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Analysartikel • May 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Embecta Corp. ( NASDAQ:EMBC ) investors will be delighted, with the company turning in some strong numbers with its...Analysartikel • Feb 21
Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend on the 15th of March, with...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Embecta tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 1,043 | 112 | 325 | 18 |
| 31 Dec 25 | 1,080 | 140 | 330 | 17 |
| 30 Sep 25 | 1,080 | 95 | 334 | 26 |
| 30 Jun 25 | 1,103 | 84 | 344 | 41 |
| 31 Mar 25 | 1,080 | 53 | 345 | 58 |
| 31 Dec 24 | 1,108 | 58 | 357 | 72 |
| 30 Sep 24 | 1,123 | 78 | 365 | 79 |
| 30 Jun 24 | 1,119 | 70 | 364 | 83 |
| 31 Mar 24 | 1,133 | 70 | 366 | 85 |
| 31 Dec 23 | 1,122 | 55 | 359 | 89 |
| 30 Sep 23 | 1,121 | 70 | 341 | 85 |
| 30 Jun 23 | 1,114 | 47 | 328 | 80 |
| 31 Mar 23 | 1,119 | 94 | 324 | 71 |
| 31 Dec 22 | 1,116 | 160 | 305 | 67 |
| 30 Sep 22 | 1,130 | 224 | 295 | 67 |
| 30 Jun 22 | 1,156 | 338 | 284 | 69 |
| 31 Mar 22 | 1,160 | 380 | 260 | 70 |
| 31 Dec 21 | 1,169 | 408 | 249 | 66 |
| 30 Sep 21 | 1,165 | 415 | 240 | 63 |
| 30 Sep 20 | 1,086 | 428 | 215 | 61 |
| 30 Sep 19 | 1,109 | 432 | 222 | 62 |
Kvalitetsintäkter: EMBC har inkomster av hög kvalitet.
Växande vinstmarginal: EMBC s nuvarande netto vinstmarginaler (10.7%) är högre än förra året (4.9%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: EMBC s intäkter har minskat med 43.6% per år under de senaste 5 åren.
Accelererande tillväxt: EMBC s intäktstillväxt under det senaste året ( 111.9% ) överstiger sitt 5-åriga genomsnitt ( -43.6% per år).
Resultat vs industri: EMBC vinsttillväxt under det senaste året ( 111.9% ) översteg Medical Equipment branschen 9.9%.
Avkastning på eget kapital
Hög ROE: EMBC s skulder överstiger dess tillgångar, så det är svårt att beräkna dess avkastning på eget kapital.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/07 12:57 |
| Aktiekurs vid dagens slut | 2026/05/07 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/09/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Embecta Corp. bevakas av 7 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |